The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECT

Steven I. Sherman, MD
Published Online: 6:10 PM, Sun March 8, 2015
Steven I. Sherman, MD, associate vice-provost for Clinical Research, professor and chair, Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial. The SELECT trial looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.

Clinical Pearls

  • One side effect of lenvatinib is that it alters the absorption of levothyroxine.
  • It was anticipated that this effect would raise serum TSH levels. This could be significant because TSH can stimulate the growth of thyroid cancer.
  • Though many patients developed increased TSH levels and needed increased dosing of thyroid hormone throughout the SELECT trial, the efficacy of lenvatinib was not affected.

<<< More from the Endo 2015 meeting

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.